Loxo
Loxo Oncology, a prominent player in the biopharmaceutical industry, is headquartered in the United States and focuses on the development of targeted therapies for cancer treatment. Founded in 2013, the company has made significant strides in precision medicine, particularly in the field of oncology, with a commitment to addressing unmet medical needs. Loxo Oncology is renowned for its innovative approach to drug development, offering unique therapies that target specific genetic mutations in tumours. Their core products, including the well-regarded Vitrakvi (larotrectinib), exemplify their dedication to personalised medicine, setting them apart in a competitive market. With a strong presence in the US and expanding operations globally, Loxo has established itself as a leader in the oncology sector, achieving notable milestones in clinical trials and regulatory approvals.
DitchCarbon Score
How does Loxo's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Loxo's score of 3 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Loxo's reported carbon emissions
Loxo, headquartered in the US, has not disclosed specific carbon emissions data for recent years. The latest available emissions data dates back to 2017, where the company reported specific greenhouse gas emissions of approximately 0.04626 kg CO2e per €1,000 in external sales, using a market-based method. This figure reflects the company's performance in managing its carbon footprint relative to its revenue. Currently, Loxo has not established any formal reduction targets or initiatives, nor have they committed to the Science Based Targets initiative (SBTi). This lack of defined climate commitments may place Loxo at a disadvantage in an industry increasingly focused on sustainability and carbon neutrality. As the global emphasis on climate action intensifies, it is crucial for Loxo to consider setting measurable targets and implementing strategies to reduce its carbon emissions across all scopes, particularly Scope 1 and 2 emissions, which pertain to direct and indirect emissions from owned or controlled sources.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Loxo is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
